Scientific Precision Meets AI Innovation

Innovation at the
Intersection of Drug
Development and Data Science

  • Extended timelines for drug approval of 10-15 years.

  • An ever-increasing average price tag to develop a drug, now at $2.6B.

  • Low approval ratings, with only 12% of new molecular entities that enter clinical trials receiving FDA approval.

  • Extended timelines for drug approval of 10-15 years.

  • An ever-increasing average price tag to develop a drug, now at $2.6B.

  • Low approval ratings, with only 12% of new molecular entities that enter clinical trials receiving FDA approval.

  • Extended timelines for drug approval of 10-15 years.

  • An ever-increasing average price tag to develop a drug, now at $2.6B.

  • Low approval ratings, with only 12% of new molecular entities that enter clinical trials receiving FDA approval.

De-Risk High Stakes Decisions

DeRisk-high-stakes-decisions

De-Risk High Stakes Decisions

De-Risk High Stakes Decisions
Clinical Development Insights

Dynamic Benchmarks

Dynamic Benchmarks

Clinical Development Insights

Data & Insights

Data & Insights

Who We Work With

Who We Work With